In this episode of the Diagnosing Health Care Podcast: When analyzing the life cycle of any health care product, a key component to consider is how much the product will cost and who will pay for it.
What unique challenges do direct access tests (DATs) pose when it comes to reimbursement and related compliance requirements?
Blog Editors
Recent Updates
- At the Half: No Free Kicks in FDA’s 2026 Enforcement
- CMS Codifies Drug Price Negotiation Program—With Modifications for 2029
- Federal Embryo Adoption Program Raises Potential Legal Questions for Reproductive Health
- Vermont’s H. 583 Restricts Private Equity and Hedge Funds with Ownership and Controlling Interests from Interfering with Clinical Judgment of Health Care Providers
- DOJ’s Second National Health Care Fraud Takedown of the Second Trump Administration Heavily Targets Medicaid Fraud